Redox Factor-1 Mediates Inflammatory Response during Tumor Promotion in Skin Epidermal JB6 Cells

Delira Robbins, Wenjuan Li, Katie Humphrey, Yunfeng Zhao

Department of Pharmacology, Toxicology & Neuroscience, Louisiana State University Health Sciences Center, Shreveport, USA.
Southwood High School, Shreveport, USA.

DOI: 10.4236/ojapo.2012.13003                

Abstract

Recently, redox factor-1 (Ref-1) has received considerable attention as an enzyme for stimulating tumor cell growth. We hypothesized that Ref-1 is upregulated during the early stage of tumorigenesis. Utilizing both tumor promotion sensitive P+ and promotion resistant P? mouse skin epidermal JB6 cells, we found that Ref-1 expression was only induced in tumor promotion sensitive P+ cells following TPA treatment. Consistent with that, Ref-1 knockdown suppressed skin cell transformation. Interestingly, Ref-1 knockdown suppressed nuclear translocation of NF-kappaB subunit p65, and inhibited production of proinflammatory cytokines. These results suggest Ref-1 may promote early tumorigenesis and serve as a target for chemoprevention.

Keywords

Ref-1; Tumorigenesis; JB6 Cells; Tumor Promotion; Chemoprevention

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	L. A. Loeb and B. D. Preston, “Mutagenesis by Apurinic/Apyrimidinic Sites,” Annual Review of Genetics, Vol. 20, 1986, pp. 201-230. doi:10.1146/annurev.ge.20.120186.001221
[2]	R. M. Schaaper, T. A. Kunkel and L. A. Loeb, “Infidelity of DNA Synthesis Associated with Bypass of Apurinic Sites,” Proceedings of the National Academy of Sciences of the United States, Vol. 80, No. 2, 1983, pp. 487-491. doi:10.1073/pnas.80.2.487
[3]	D. M. Wilson and D. Barsky, “The Major Human Abasic Endonuclease: Formation, Consequences and Repair of Abasic Lesions in DNA,” Mutation Research, Vol. 485, No. 4, 2001, pp. 283-307. doi:10.1016/S0921-8777(01)00063-5
[4]	A. R. Evans, M. Limp-Foster and M. R. Kelley, “Going APE over Ref-1,” Mutation Research, Vol. 461, No. 2, 2000, pp. 83-108. doi:10.1016/S0921-8777(00)00046-X
[5]	B. Muller-Hubenthal, M. Azemar, D. Lorenzen, M. Huber, M. A. Freudenberg, et al., “Tumor Biology: Tumour- Associated Inflammation versus Antitumor Immunity,” Anticancer Research, Vol. 29, No. 11, 2009, pp. 4795- 4806.
[6]	M. H. Han, W. K. Yon, H. Lee, et al., “Topical Application of Silymarin Reduces Chemical-Induced Irritant Contact Dermatitis in BALB/c Mice,” International Immunopharmacology, Vol. 7, No. 13, 2007, pp. 1651-1658. doi:10.1016/j.intimp.2007.08.019
[7]	P. C. Taylor, A. M. Peters, E. Paleolog, et al., “Reduction of Chemokine Levels and Leukocyte Traffic to Joints by Tumor Necrosis Factor Alpha Blockade in Patients with Rheumatoid Arthritis,” Arthritis & Rheumatism, Vol. 43, No. 1, 2000, pp. 38-47. doi:10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L
[8]	E. Van Coillie, J. Van Damme and G. Opdenakker, “The MCP/Eotaxin Subfamily of CC Chemokines,” Cytokine Growth Factor Reviews, Vol. 10, No. 1, 1999, pp. 61-86. doi:10.1016/S1359-6101(99)00005-2
[9]	M. Tucci, C. Quatraro, M. A. Frassanito and F. Silvestris, “Deregulated Expression of Monocyte Chemoattractant Protein-1 (MCP-1) in Arterial Hypertension: Role of Endothelial Inflammation and Atheromasia,” Journal of Hypertension, Vol. 24, 2006, pp. 1307-1318. doi:10.1097/01.hjh.0000234111.31239.c3
[10]	M. O’Hayre, C. L. Salanga, T. M. Handel and S. J. Allen, “Chemokines and Cancer: Migration, Intracellular Signaling and Intercellular Communication in the Microenvironment,” Biochemical Journal, Vol. 409, No. 3, 2008, pp. 635-649. doi:10.1042/BJ20071493
[11]	J. Zhang, L. Chen, M. Xiao, et al., “FSP1+ Fibroblasts Promote Skin Carcinogenesis by Maintaining MCP-1 Mediated Macrophage Infiltration and Chronic Inflammation,” American Journal of Pathology, Vol. 178, No. 1, 2011, pp. 382-390. doi:10.1016/j.ajpath.2010.11.017
[12]	A. Kapp, G. Zeck-Kapp, W. Czech and E. Schopf, “The Chemokine RANTES is More than a Chemoattractant: Characterization of Its Effect on Human Eosinophil Oxidative Metabolism and Morphology in Comparison with IL-5 and GM-CSF,” Journal of Investigative Dermatology, Vol. 102, No. 6, 1994, pp. 906-914. doi:10.1111/1523-1747.ep12383399
[13]	S. Kakolyris, L. Kaklamanis, A. Giatromanolaki, M. Koukourakis, S. I. D. Hickson, et al., “Expression and Subcellular Localization of Human AP Endonuclease 1 (HAP1/Ref-1) Protein: A Basis for Its Role in Human Disease,” Histopath, Vol. 33, No. 6, 1998, pp. 561-569. doi:10.1046/j.1365-2559.1998.00541.x
[14]	N. H. Colburn, B. F. Former, K. A. Nelson and S. H. Yuspa, “Tumour Promoter Induces Anchorage Independence Irreversibly,” Nature, Vol. 281, 1979, pp. 589- 591. doi:10.1038/281589a0
[15]	Y. Xu, D. H. Moore, J. Broshears, L. Liu, T. M. Wilson, et al., “The Apurinic/Apyrimidinic Endonuclease (APE/ Ref-1) DNA Repair Enzyme Is Elevated in Pre-Malignant and Malignant Cervical Cancer,” Anticancer Research, Vol. 17, No. 5B, 1997, pp. 3713-3719.
[16]	D. H. Moore, H. Michael, R. Tritt, S. H. Parsons and M. R. Kelley, “Alterations in the Expression of the DNA Repair/Redox Enzyme APE/Ref-1 in Epithelial Ovarian Cancers,” Clinical Cancer Research, Vol. 6, No. 2, 2000, pp. 602-609.
[17]	K. Ando, S. Hirao, Y. Kabe, Y. Ogura, I. Sato, Y. Yamaguchi, T. Wada and H. Handa, “A New APE1/Ref-1- Dependent Pathway Leading to Reduction of NF-Kappab and AP-1, and Activation of Their DNA-Binding Activity,” Nucleic Acids Research, Vol. 36, No. 13, 2008, pp. 4327-4336. doi:10.1093/nar/gkn416
[18]	J. Liu, X. Gu, D. Robbins, G. Li, R. Shi, et al., “Protandim, a Fundamentally New Antioxidant Approach in Chemoprevention Using mouse Two-Stage Skin Carcinogenesis as a Model,” PLoS One, Vol. 4, No. 4, 2009, p. e5284. doi:10.1371/journal.pone.0005284
[19]	Y. Zhao, L. Chaiswing, T. D. Oberley, I. Batinic-Harberle, W. St. Clair, et al., “A Mechanism-Based Antioxidant Approach for the Reduction of Skin Carcinogenesis,” Cancer Research, Vol. 65, No. 4, 2005, pp. 1401-1405. doi:10.1158/0008-5472.CAN-04-3334
[20]	Y. Zhao, Y. Xue, T. D. Oberley, K. K. Kiningham, S. M. Lin, et al., “Overexpression of Manganese Superoxide Dismutase Suppresses Tumor Formation by Modulation of Activator Protein-1 Signaling in a Multistage Skin Carcinogenesis Model,” Cancer Research, Vol. 61, No. 16, 2001, pp. 6082-6088.
[21]	Y. Zhao, K. K. Kiningham, S. M. Lin and D. K. St. Clair, “Overexpression of MnSOD Protects Murine Fibrosarcoma Cells (FSa-II) from Apoptosis and Promotes a Differentiation Program upon Treatment with 5-Azacytidine: Involvement of MAPK and NFkappaB Pathways,” Antioxidants & Redox Signaling, Vol. 3, No. 3, 2001, pp. 375-386. doi:10.1089/15230860152409022
[22]	S. Grosch, G. Fritz and B. Kaina, “Apurinic Endonuclease (Ref-1) Is Induced in Mammalian Cells by Oxidative Stress and Is Involved in Clastogenic Adaptation,” Cancer Research, Vol. 58, No. 19, 1998, pp. 4410-4416.
[23]	C. V. Ramana, I. Boldogh, T. Izumi and S. Mitra, “Activation of Apurinic/Apyrimidinic Endonuclease in Human Cells by Reactive Oxygen Species and Its Correlation with Their Adaptive Response to Genotoxicity of Free Radicals,” Proceedings of the National Academy of Sciences of United States, Vol. 95, No. 9, 1998, pp. 5061- 5066. doi:10.1073/pnas.95.9.5061
[24]	A. Unnikrishnan, J. J. Raffoul, H. V. Patel, T. M. Prychitko, N. Anyangwe, et al., “Oxidative Stress Alters Base Excision Repair Pathway and Increases Apoptotic Response in Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Haploinsufficient Mice,” Free Radical Biology & Medicine, Vol. 46, No. 11, 2009, pp. 1488-1499.
[25]	J. L. Hall, X. Wang, V. Adamson, Y. Zhao and G. H. Gibbons, “Overexpression of Ref-1 Inhibits Hypoxia and Tumor Necrosis Factor-Induced Endothelial Cell Apoptosis through Nuclear Factor-κB-Independent and -Dependent Pathways,” Circulation Research, Vol. 88, 2001, pp. 1247-1253. doi:10.1161/hh1201.091796
[26]	M. Z. Hadi, M. A. Coleman, K. Fidelis, H. W. Mohrenweiser and D. M. Wilson III, “Functional characterization of Ape1 variants identified in the human population,” Nucleic Acids Research, Vol. 28, No. 20, 2000, pp. 3871- 3879. doi:10.1093/nar/28.20.3871